Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

A Phase II trial of OSI-774 (Tarceva) in patients with Recurrent Malignant Gliomas not on EIAEDs

A Phase II trial of OSI-774 (Tarceva) in patients with Recurrent Malignant Gliomas not on EIAEDs. Proc ASCO. 2004.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.